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Abstract
As shown by transgenic mouse models and by using phosphodiesterase 3 (PDE3) inhibitors, PDE3B has an important role in
the regulation of insulin secretion in pancreatic b-cells. However, very little is known about the regulation of the enzyme.
Here, we show that PDE3B is activated in response to high glucose, insulin and cAMP elevation in rat pancreatic islets and
INS-1 (832/13) cells. Activation by glucose was not affected by the presence of diazoxide. PDE3B activation was coupled to
an increase as well as a decrease in total phosphorylation of the enzyme. In addition to PDE3B, several other PDEs were
detected in human pancreatic islets: PDE1, PDE3, PDE4C, PDE7A, PDE8A and PDE10A. We conclude that PDE3B is activated
in response to agents relevant for b-cell function and that activation is linked to increased as well as decreased
phosphorylation of the enzyme. Moreover, we conclude that several PDEs are present in human pancreatic islets.
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Introduction
Cyclic nucleotide phosphodiesterases (PDEs) are enzymes with
the function to hydrolyze cyclic AMP (cAMP) and cyclic GMP
(cGMP) [1,2]. There are eleven known PDE families (PDE1-11)
with a total of 21 gene products and 100 resulting mRNA products
[1,2]. The PDE families differ in primary structures, affinities for
cAMP and cGMP, responses to specific effectors, sensitivities to
specific inhibitors, mechanisms whereby they are regulated,
cellular expression and intracellular location [1,2]. Indeed, it is
believed that individual isozymes modulate distinct regulatory
pathways within the cell [1,2]. Family-selective PDE inhibitors
available for several PDEs have been very useful in dissecting out
specific functions for selected PDEs and are also used in the clinic,
as well as being developed for the treatment of various diseases
[1,2].
It is well established that PDE1, PDE3, and PDE4 are expressed
in rodent pancreatic islets and b-cells [3,4,5,6,7,8,9,10]. Further-
more, several studies have shown that family-selective inhibition of
PDE1, PDE3 and to some extent also PDE4 potentiates glucose-
stimulated insulin secretion (GSIS) [3,4,10,11,12]. More recently
mRNAs for PDE1B-C, PDE2A, PDE3A-B, PDE4A-D, PDE5A,
PDE8A-B, PDE9A, PDE10A and PDE11A as well as the proteins
PDE3A-B, PDE4B and PDE8A have been detected in rodent
pancreatic islets and b-cell lines [8,10,11,13]. Of these PDEs,
PDE8B and PDE10A have potential in the context of b-cell
function, since diminished activity of PDE8B [13] as well as
PDE10A inhibition [14] potentiated insulin secretion in response
to glucose in rat pancreatic islets.
With regard to PDE3B, its physiological and functional role has
been extensively studied in pancreatic b-cells in vivo and in vitro
[7,8,11,15]. It has been shown that b-cell PDE3B is localized to
the insulin granules and the plasma membrane, where it appears
to regulate the acute first phase and the second sustained phase of
insulin secretion [8]. Further, RIP-PDE3B mice overexpressing
PDE3B specifically in b-cells show impaired GSIS as well as
cAMP-potentiated GSIS, impaired glucose tolerance and in-
creased sensitivity to high-fat induced insulin resistance
[7,8,11,15]. Thus, it appears that PDE3B has an important role
in pancreatic b-cells with regard to the regulation of insulin
secretion and also the regulation of whole body energy
homeostasis in mice. However, very little is known about the
regulation of PDE3B activity in b-cells. Also, the information is
sparse with regard to the expression and activity pattern of PDEs
in human pancreatic islets. To our knowledge one study, however,
indicates the presence of PDE3 and PDE4 activities as well as
modest activity of PDE1 in human islets, and inhibition of PDE3,
but not PDE1 and PDE4, was shown to increase insulin secretion
[9].
The aim of this work was to study (a) the alterations in PDE3B
activity and phosphorylation state in response to agents of
relevance for insulin secretion as well as (b) the expression and
activity of selected PDEs in human pancreatic islets. We show that
glucose and insulin, as well as forskolin, a cAMP-elevating agent,
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14191activate PDE3B in rat pancreatic islets and/or INS-1 (832/13)
cells. The activation was associated with altered phosphorylation
states of the enzyme. We also show that PDE1, PDE3, PDE4C,
PDE7A, PDE8A and PDE10A are expressed in human pancreatic
islets.
Materials and Methods
2.1 Animal Model
Sprague Dawley rats were purchased from Charles River
Laboratories (Germany) and kept under standardized conditions
in the animal house facilities. All experimental procedures have
been approved by the Committee of ethical animal research in
Malmo ¨ and Lund (permission number: M166-08).
2.2 Cell Culture
The rat insulinoma cell line INS-1 (832/13) [a modified INS-1
cell clone, stably transfected with the human proinsulin gene) [16]
(passages 70–90)], was kept in RPMI 1640 (Sigma), containing
11 mM glucose and supplemented with 10% fetal calf serum, 100
units/ml penicillin, 100 mg/ml streptomycin, and 50 mM b-
mercaptoethanol. The cells were grown at 37uC in an atmosphere
of 5% CO2 and 95% air.
2.3 Isolation of Pancreatic Rat Islets
Pancreatic islets from 5–6 weeks old male Sprague Dawley rats
were isolated by a collagenase digestion technique [15]. In short,
the common bile duct was cannulated and ligated at the Papilla
Vateri. The pancreas was filled with 10 ml of ice-cold Hank’s
balanced salt solution (HBSS) (Sigma-Aldrich) supplemented with
1.3 units/ml Collagenase P (Roche), removed and then incubated
at 37uC for 23 minutes. After a few washes in HBSS, pancreatic
islets were collected under a stereomicroscope and incubated at
37uC overnight in RPMI 1640, supplemented with 5 mM glucose
(Invitrogen).
2.4 Treatment of Cells and Rat Pancreatic islets
Rat pancreatic islets or INS-1 (832/13) cells were pre-incubated
for 2 hours in Krebs-Ringer bicarbonate buffer (KRBB) contain-
ing 1 mM glucose, 10 mM Hepes, pH 7.2–7.4, 120 mM NaCl,
5 mM NaHCO3, 5 mM KCl, 1.2 mM KH2PO4, 2.5 mM CaCl2,
1.2 mM MgSO4, and 0.2% BSA. The buffer was changed and
islets (80–140 islets per stimulus) or cells were stimulated with
KRBB supplemented with 16 mM glucose, 100 nM insulin or
100 mM forskolin. In some experiments, islets were first incubated
in 250 mM diazoxide (in KRBB supplemented with 1 mM glucose)
for 30 minutes and then stimulated with 16 mM glucose. For K
+-
stimulation the buffer was changed to KRBB, containing 10 mM
Hepes, pH 7.2–7.4, 60 mM NaCl, 5 mM NaHCO3, 60 mM KCl,
1.2 mM KH2PO4, 2.5 mM CaCl2, 1.2 mM MgSO4, and 0.2%
BSA, supplemented with 1 mM glucose. After 1 hour stimulation,
islets or cells were harvested in a buffer containing 50 mM TES,
pH 7.4, 250 mM sucrose, 1 mM EDTA, 2 mM EGTA, 40 mM
phenyl-phosphate and 5 mM NaF supplemented with Complete
Protease Inhibitor Cocktail (containing inhibitors for serine-,
cysteine- and metalloproteases as well as calpains) (Roche) and
homogenized by 10 short sonication pulses. The homogenates
were briefly centrifuged to remove cell debris. Total protein
amount was determined according to Bradford [17] and PDE3
activity was measured (15 islets per assay tube) as described below.
2.5 Treatment of Human Pancreatic islets
Human islets from non-diabetic individuals were provided by
the Nordic Network for Clinical Islet Transplantation (O.
Korsgren, Uppsala University, Sweden) and characterized by the
Human Tissue Laboratory (Jalal Taneera, Lund University
Diabetes Centre, Sweden). All experimental procedures have
been approved by the Regional ethical committee in Lund
(permission number: 173/2007). Frozen human pancreatic islets
were thawed, resuspended in a buffer containing 50 mM TES,
pH 7.4, 250 mM sucrose, 1 mM EDTA, and 0.1 mM EGTA,
supplemented with Complete Protease Inhibitor Cocktail (Roche)
and homogenized by 10 short sonication pulses. Total protein
amount was determined according to Bradford [17].
2.6 PDE Assay
PDE activity was measured in duplicates as described [18] in
the presence or absence of family-selective PDE inhibitors. The
following PDE inhibitors were used: 3 mM of the PDE3 inhibitor
OPC3911 (Osaka Inc. Japan), 10 mM of the PDE4 inhibitor RO-
20-1724 (Roche) or 50 mM of the PDE1 inhibitor 8MM-IBMX
(Biomol). Assays were performed at 30uC in a total volume of
300 ml of buffer containing 50 mM TES pH 7.4, 250 mM
sucrose, 1 mM EDTA, 0.1 mM EGTA, and 8.3 mM MgCl2,
0.5 mM cAMP, 0.5 mg ovalbumin and 1 mCi/ml [3H] cAMP.
2.7 Adenovirus Infection
To overexpress PDE3B INS-1 (832/13) cells were infected with
an adenovirus expressing flag-tagged mouse PDE3B (AdPDE3B)
[11] or a control virus expressing b-galactosidase (Adb-gal). High
titer viral stocks (,10
10 pfu/ml) were used to infect cells kept in
RPMI 1640 (Invitrogen), containing 11 mM glucose, for 2 hours.
For experiments, conducted 18 hours post infection, cells were
treated as described above.
2.8
32P labelling and Treatment of INS-1 (832/13) Cells
AdPDE3B-infected INS-1 (832/13) cells (see above) were
washed in low phosphate KRBB (LP-KRBB) (10 mM Hepes,
pH 7.2–7.4, 120 mM NaCl, 5 mM NaHCO3, 5 mM KCl, 50 mM
KH2PO4, 2.5 mM CaCl2, 1.2 mM MgSO4, and 0.2% BSA) and
pre-incubated in LP-KRBB containing 1 mM glucose and
32Pa t
0.2 mCi/ml for 2 hours. The cells were stimulated at 37uC for
1 hour and homogenized (sonication, 10 pulses) on ice in 50 mM
TES, pH 7.4, 250 mM sucrose, 1 mM EDTA, 2 mM EGTA,
40 mM phenyl-phosphate, 5 mM NaF, 1 mM DTE, 50 mM
vanadate, 1 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml antipain
and 1 mg/ml pepstatin A. The homogenate was centrifuged at
175,0006ga t4 uC for 1 h and the crude membrane fraction was
resuspended and homogenized in the homogenization buffer
described above, supplemented with 1% C13E12 (non-ionic alkyl
polyoxyethylene glycol detergent from Berol Kemi AB, Stenung-
sund, Sweden).
2.9 Subcellular Fractionation
Cells were washed three times with chilled homogenization
buffer containing 250 mM sucrose, 0.5 mM EGTA, 5 mM
HEPES adjusted with KOH to pH 7.4, supplemented with
10 mg/ml leupeptin, 10 mg/ml antipain and 1 mg/ml pepstatin
(Peptide Institute Inc., Osaka, Japan), 5 mM NaF, 1 mM DTE,
50 mM vanadate and 1 mM PMSF. Cells were harvested in
homogenization buffer and disrupted under 350 psi of nitrogen in
a Parr bomb (Parr Instrument Company, Illinois, USA) for 15 min
at 4uC. A fraction of the homogenate was centrifuged at 7006g
for 15 min at 4uC and the resulting supernatant was mixed with
sucrose (final concentration 250 mM) and Percoll (15% of final
mixture). A self-generating gradient was produced through
centrifugation at 48,0006 g for 25 min in a fixed angle rotor.
Phosphodiesterases in b-cells
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were collected and washed three times in 4 volumes of
homogenization buffer through 150,0006 g centrifugation at
4uC for 30 min. The cytosol fraction was obtained by centrifu-
gation of the homogenate at 150,0006ga t4 uC for 60 min.
2.10 SDS-PAGE and Immunoblot Analysis
Homogenates from cells, islets or immuno-precipitates were
subjected to SDS-PAGE. Proteins were electrotransferred to
polyvinylidene membranes (Millipore) and the membranes were
stained with Ponceau S (0.1% in 5% acetic acid) and then blocked
with 5% milk in a buffer consisting of 20 mM Tris-HCl, pH 7.6,
137 mM NaCl and 0.1% (v/w) Tween-20 for 30–60 min.
Membranes with proteins from cells or immuno-precipitates were
probed with PDE3B antibodies (prepared against the peptide
CGYYGSGKMFRRPSLP from rat PDE3B sequence [19]), or
mouse monoclonal anti-Na
+/K
+-ATPase antibodies, for 16 h.
Membranes with proteins from human islets were probed with the
following antibodies: PDE4C, PDE7A, PDE8A or PDE10A
(Scottish Biomedical), and incubated overnight. Proteins were
detected using the chemiluminescent Super Signal West Pico
Luminol/Enhancer solution from Pierce (Illinois, USA) and a Fuji
LAS 1000 Plus system or a Fuji LAS 3000 Plus system (Fuji Photo
Film Co., Ltd, Tokyo, Japan).
2.11 Statistics
Data are presented as means 6 SEM from the indicated
number of experiments. Statistically significant differences were
analyzed using Wilcoxon’s Signed Rank test or Student’s t-test
with significance levels *p,0.05, **p,0.01 and ***p,0.001.
Results
3.1 Activation of PDE3B in rat pancreatic islets and INS-1
(832/13) cells
Glucose-stimulated insulin secretion (GSIS) involves metaboli-
zation of glucose, which generates an increase in intracellular ATP
followed by closing of the ATP sensitive KATP channels [20]. This
closure results in membrane depolarization, opening of voltage-
dependent Ca
2+ channels and an influx of Ca
2+, which triggers
exocytosis of insulin granules [20]. GSIS is potentiated by
hormones that increase cAMP, such as the incretins glucagon like
peptide-1 (GLP-1) and glucose-dependent insulinotropic polypep-
tide (GIP) [21,22,23]. Also, insulin has been shown to induce
inhibition as well as stimulation of GSIS [24].
Activation of PDE3B was studied in rat pancreatic islets and rat
derived INS-1 (832/13) cells. As shown in Fig. 1, high glucose
(16 mM for 1 h), the main trigger of insulin secretion, resulted in
activation of PDE3 in rat islets (Fig. 1A) and INS-1 (832/13) cells
(Fig. 1B). Since insulin is a well known activator of PDE3B in
adipocytes and hepatocytes [25,26] we wanted to test the
possibility that the insulin released from islets or INS-1 (832/13)
cells could activate b-cell PDE3B and thus mediate the glucose-
induced activation of PDE3B. As seen in Fig. 1, indeed,
exogenously added insulin induced activation of PDE3B in islets
(Fig. 1A) and INS-1 (832/13) cells (Fig. 1B). To elucidate if the
glucose effect on PDE3B was dependent on the release of
endogenously produced insulin, islets were treated with high
glucose in the presence or absence of diazoxide. Diazoxide is a
KATP channel-activator that hyperpolarizes the b-cell and
prevents insulin secretion even in the presence of glucose. As
shown in Fig. 1C, diazoxide did not inhibit glucose-mediated
activation of PDE3B, indicating that glucose is not mediating its
effect via endogenously produced insulin.
Figure 1. Activation of PDE3B in rat pancreatic islets and INS-1
(832/13) cells. Isolated rat pancreatic islets (A) or cells (B) were pre-
incubated in low glucose for 2 hours and then stimulated with 16 mM
glucose (glu), 100 nM insulin (ins), 60 mM K
+ or 100 mM forskolin (fsk)
for 1 hour. Isolated pancreatic islets (C) were pre-incubated in low
glucose for 2 hours, pre-incubated in the presence or absence of
250 mM diazoxide (diaz) for 30 minutes and then stimulated with
16 mM glucose for 1 hour. Pancreatic islets or cells were homogenized
and PDE3 activity was measured (n=5–7 for A, n=4 for B and n=10 for
C).
doi:10.1371/journal.pone.0014191.g001
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b-cell mediated independently of glucose would activate PDE3B.
For that purpose, cells and islets were stimulated with high
(60 mM) K
+ under non- stimulatory glucose conditions (1 mM),
the rational for which is that elevated K
+ concentration
depolarizes the b-cell and directly triggers insulin secretion, thus
bypassing glucose metabolism. As shown in Fig. 1, high K
+
induced activation of PDE3B, indicating that metabolization of
glucose is not necessary for activation of the enzyme. Islets and
cells were also treated with forskolin, an agent known to activate
adenylyl cyclases, leading to increased intracellular cAMP. As
shown in Fig. 1, stimulation of rat pancreatic islets (Fig. 1A) and
INS-1 (832/13) cells (Fig. 1B) with forskolin resulted in activation
of PDE3B.
3.2 Phosphorylation of PDE3B in response to glucose,
insulin and forskolin
Initial experiments showed that in
32P-labelled INS-1 (832/13)
cells, endogenous PDE3B was not present in sufficient amounts to
be detected as a
32P-phosphorylated protein. Thus, to be able to
study phosphorylation of PDE3B in b-cells we overexpressed
PDE3B using an adenoviral system. The recombinant enzyme
(AdPDE3B) was characterized with regard to expression level,
localization and ability to be activated. We found that infection of
INS-1 (832/13) cells with AdPDE3B virus resulted in a ,10-fold
overexpression of PDE3B compared to control Adb-gal infected
cells (Fig. 2A) and that
32P-PDE3B was detected after immuno-
precipitation using both PDE3B antibody and an anti-flag M2
affinity gel (Fig. 2B), as well as using mass spectrometry (data not
shown). To establish the intracellular localization of overexpressed
PDE3B, INS-1 (832/13) cells expressing recombinant PDE3B
were subjected to subcellular fractionation and subsequent
immunoblotting. Fig. 2C demonstrates that, similar to endogenous
PDE3B [8], recombinant PDE3B localizes to the granule and
plasma membrane fractions, respectively. There is also a clear
presence of recombinant PDE3B in the cytosol fraction not seen in
control infected cells. A likely explanation could be that the
membranes are saturated with PDE3B proteins as a consequence
of overexpression.
To evaluate the functionality of recombinant PDE3B, activation
studies were conducted in AdPDE3B-infected INS-1 (832/13)
cells. Infected INS-1 (832/13) cells were stimulated with 16 mM
glucose, 100 nM insulin or 60 mM K
+ and PDE3 activity was
measured in homogenates. The stimuli resulted in activation of
PDE3B although to a lesser degree than in experiments including
endogenous PDE3B (Fig. 2D). Nevertheless, this indicates that the
recombinant enzyme is responding properly to stimuli in infected
cells.
To study phosphorylation of PDE3B, AdPDE3B-infected INS-
1 (832/13) cells were
32P-labelled and treated with various agents
as indicated in Fig. 3. PDE3B was immunoprecipitated and
subjected to SDS-PAGE, immunoblot analysis and autoradiog-
raphy. Stimulation with 16 mM glucose for 1 hour resulted in a
significant, 45% reduction in the phosphorylation of PDE3B
(Fig. 3A), in a dose-dependent manner (Fig. 3B). However,
stimulation with 100 nM insulin did not result in any apparent
change in the amount of phosphorylation of PDE3B (Fig. 4A).
On the other hand, the phosphatase inhibitor calyculin A
(100 nM) induced a marked increase in the phosphorylation of
PDE3B. Also, a marked increase in the phosphorylation of
PDE3B was seen when the cAMP-elevating agent forskolin
(100 nM) (Fig. 4B) was included, as compared to non-stimulated
cells.
3.3 PDEs in human pancreatic islets
The enzymatic activity and expression of selected PDEs were
studied in human pancreatic islets. Isolated human islets were
homogenized and enzymatic activity of PDE1, PDE3, and PDE4
was measured. As shown in Fig. 5A, PDE1, PDE3, and PDE4
each contribute with ,30–37% of the total PDE activity in human
islets.
To identify the expression of selected PDEs, human islets were
homogenized and proteins were subjected to immunoblot analysis
using antibodies against PDE4C, PDE7A, PDE8A and PDE10A.
Fig. 5B shows the expression of PDE isoforms in islets from three
human donors identified by immunoblot analysis. As shown in
Fig. 5B, we could detect PDE4C, PDE7A, PDE8A and PDE10A.
Taken together, these results show that PDE1, PDE3, PDE4C,
PDE7A, PDE8A and PDE10A are present in human pancreatic
islets.
Discussion
We have studied the regulation of the cAMP-degrading enzyme
PDE3B in rodent pancreatic islets and insulin secreting cells.
PDE3B was found to be activated in response to stimuli that are
relevant for pancreatic b-cell function and increased PDE3B
activity was associated with changes in the state of phosphorylation
of the enzyme. In addition, the expression of a number of PDEs in
human pancreatic islets was investigated. Thus, in human
pancreatic islets activities of PDE1, PDE3 and PDE4 and
expression of PDE4C, PDE7A, PDE8A and PDE10A proteins
were demonstrated.
PDE3B is expressed in adipose tissue, liver, pancreatic b-cells,
and hypothalamus and has been found to regulate many metabolic
events central to whole body energy homeostasis [27,28]. In
particular, PDE3B regulates lipid and glucose metabolism in
adipocytes [29,30] and hepatocytes [31], insulin secretion in
pancreatic b-cells [11,15] as well as leptin action in hypothalamus
and pancreatic b-cells [28,32]. In adipocytes, insulin-mediated
activation of PDE3B has a key role in antagonizing cAMP-
mediated lipolysis [33,34] and in hepatocytes, insulin-mediated
activation of the enzyme is believed to contribute to antagoniza-
tion of cAMP-mediated glycogenolysis [35]. Thus, the finding that
insulin induces activation of PDE3B in b-cell is in agreement with
PDE3B as a target for insulin action also in this cell type. With
regard to the role of PDE3B activation in response to insulin, it has
been shown that leptin and IGF-1 attenuate insulin secretion in a
PDE3B-dependent manner in HIT-T15 cells [6,36]. In the
present work, glucose stimulation of rodent islets and b-cells was
found to activate PDE3B. Although glucose is the major trigger of
insulin release and exogenously added insulin was shown to
activate PDE3B in pancreatic islets and b-cells, glucose-stimulated
activation of PDE3B is most likely not mediated by an insulin-
dependent mechanism. This is based on the finding that diazoxide
did not inhibit glucose-stimulated activation of PDE3B.
The finding that high K
+ (elevated K
+ concentration depolar-
izes the b-cell and triggers Ca
2+ influx and insulin secretion, thus
bypassing glucose metabolism) induces activation of PDE3B
suggests that glucose-induced activation of PDE3B may be
mediated downstream of the metabolization of the sugar, maybe
at the level of Ca
2+ influx. It is known that increased Ca
2+ gives
rise to increased cAMP levels via activation of Ca
2+-dependent
adenylyl cyclases [20,37]. Thus, it is possible that glucose mediates
its effect on PDE3B via a cAMP-dependent mechanism [38]. This
is compatible with the finding that the cAMP-elevating agent
forskolin induced activation of PDE3B and also in agreement with
previous results demonstrating activation of PDE3B in response to
Phosphodiesterases in b-cells
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[33,34].
The consequence of activation of PDE3B is expected to be a
faster turnover of cAMP and essentially an attenuation of insulin
secretion as cAMP has an established role as a potentiator of
insulin secretion through PKA-dependent and PKA-independent
mechanisms. Thus, we hypothesize that PDE3B activation by
glucose, insulin and cAMP-elevating agents constitute a feedback
loop to constrain and direct cAMP signals. These results are in
agreement with previous studies by us showing that chronic
overexpression of PDE3B in b-cells in mice results in reduced
insulin secretion [7,39].
Figure 2. Characterization of AdPDE3B-overexpressed PDE3B
in INS-1 (832/13) cells. A. INS-1 (832/13) cells were infected with
either Ad-bgal or AdPDE3B virus for 2 hours, 16 hours prior to
experiment. Cells were homogenized and analyzed by PDE3 activity
assay or immunoblot analysis using anti-PDE3B antibody. B. Immunoi-
solation of recombinant
32P-labelled PDE3B from AdPDE3B infected INS-
1 (832/13) cells. A crude membrane fraction was used as starting
material for immunoprecipitation using anti-PDE3B antibody or anti-
flag M2 gel. Thoroughly washed immunoprecipitates were run on SDS-
PAGE and transferred to nitrocellulose membranes. Membranes were
subjected to autoradiography, immunoblot analysis using anti-PDE3B
antibodies and Ponceau S staining, respectively. C. Adb-gal or
AdPDE3B-infected INS-1 (832/13) cells were subjected to subcellular
fractionation using density gradient centrifugation (Percoll
TM). Cytosol
(Cyt), granule (Gran) and plasma membrane (PM) fractionations were
prepared and analyzed with immunoblot analysis for PDE3B expression.
The purity of the fractions was evaluated by immunoblot analysis of the
plasma membrane marker Na
+/K
+-ATPase (n=2). D. Cells were
AdPDE3B-infected, pre-incubated in low glucose for 2 hours and then
stimulated with 16 mM glucose, 100 nM insulin or 60 mM K
+ for 1 hour.
Cells were homogenized and PDE3 activity was measured (n=3).
doi:10.1371/journal.pone.0014191.g002
Figure 3. Phosphorylation of PDE3B in response to stimulation
with glucose in INS-1 (832/13) cells. Recombinant
32P-labelled
PDE3B was immunoprecipitated and solubilized from crude mem-
branes, run on SDS-PAGE, subjected to autoradiography and immuno-
blot analysis (one representative experiment shown). A. Stimulation
with 16 mM glucose for 1 hour (n=5). B. Stimulation with increasing
glucose concentrations for 1 h. Quantification was made using a Fuji
LAS 3000 Plus system.
doi:10.1371/journal.pone.0014191.g003
Phosphodiesterases in b-cells
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extensively studied in adipocytes [36,40,41] and partly in
hepatocytes [42] but there are no previous reports concerning
phosphorylation of PDE3B in pancreatic b-cells. To be able to
study PDE3B activation and phosphorylation in b-cells we used an
adenovirus-mediated expression system to overexpress PDE3B.
Notably, control experiments with recombinant PDE3B in INS-1
(832/13) cells showed that it could be activated and was localized
to the same intracellular compartments as is endogenous PDE3B.
Further, we have previously shown that recombinant PDE3B
attenuates glucose-induced insulin secretion and GLP-1-potenti-
ated insulin secretion [8,11].
In agreement with results from adipocytes and hepatocytes,
forskolin-induced activation of PDE3B was coupled to an
increased total phosphorylation of PDE3B. However, glucose-
stimulated activation of PDE3B was coupled to a decrease in total
phosphorylation of PDE3B. This is the first time that an increase
in PDE3B activity has been coupled to a decrease in total
phosphorylation of the enzyme, which could be explained by a
glucose-induced activation of a phosphatase dephosphorylating an
‘‘inhibitory’’ phosphorylation site in PDE3B. PP1 and PP2A (ser/
thr phosphatases) are the primary phosphatases found in insulin-
secreting cells [43,44]. Indeed, it was recently shown that glucose
itself or glucose metabolites can inhibit [45] as well as enhance
[46] protein phosphatase activities in insulin-secreting cells. To this
end, we have not been able to identify a glucose-stimulated
Figure 4. Phosphorylation of PDE3B in response to insulin,
forskolin and calyculin A. Immunoprecipitated recombinant
32P-labelled PDE3B from crude membranes were run on SDS-PAGE,
subjected to autoradiography and immunoblotting (one representative
experiment shown). Quantification was made using Fuji LAS 3000 Plus
system (n=4 for A and n=2 for B).
doi:10.1371/journal.pone.0014191.g004
Figure 5. Activity and expression of PDEs in human pancreatic
islets. A. Human islets were homogenized and total PDE, PDE1, PDE3
and PDE4 activity was measured (n=3). B. 20–25 mgo fi s l e t
homogenates from three different human donors were run on SDS-
PAGE and transferred to nitrocellulose membranes. Membranes were
subjected to immunoblotting using PDE-isoform selective antibodies
(one representative experiment shown).
doi:10.1371/journal.pone.0014191.g005
Phosphodiesterases in b-cells
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enzyme. One challenge is the fact that the specificity of
phosphatases is determined by a number of different regulatory
subunits localized to different locations in the cell.
Stimulation with calyculin A, a phosphatase inhibitor, resulted
in a 6-fold increase in PDE3B phosphorylation. However, hitherto
we have not been able to detect changes in PDE3B phosphory-
lation as a result of insulin stimulation. To detect insulin-induced
alterations in phosphorylation, it may be necessary to study
changes in the phosphorylation of unique phosphorylation sites in
PDE3B. In adipocytes, both protein kinase B (PKB) and protein
kinase A (PKA) have been suggested kinases for PDE3B
[25,36,41,47] and several phosphorylation sites have been
identified and shown to be specific for activation by, for example,
insulin and isopreterenol [40,42]. Thus, as it has not been
established which kinases phosphorylate PDE3B in b-cells, we
suggest that forskolin and insulin as well as calyculin A induce
phosphorylation of PDE3B, presumably by activating PKA and
PKB, respectively.
Several PDEs were detected in human pancreatic islets
including PDE1, PDE3, PDE4C, PDE7A, PDE8A and PDE10A.
PDE1, PDE3, and PDE4 activities were estimated using family-
selective PDE inhibitors in enzyme assays, whereas the other PDEs
were detected using immunoblot analysis. With regard to PDE4,
only PDE4C (not PDE4A, B and D) was detected, indicating that
PDE4C is the major isoform in human islets. Previously, one single
study has shown the presence of PDE3 and PDE4 activities as well
as modest activity of PDE1 in human islets [9] and, importantly,
that PDE3 inhibition resulted in increased insulin secretion.
With regard to PDEs as potential targets for modulating insulin
secretion, a recent study showed that inhibitors selective for
PDE10A acted as insulin secretagogues [14] in rat pancreatic
islets. Another study stated that siRNA-mediated silencing of
PDE8B enhanced GSIS, whereas inhibition of PDE10A did not
have a significant effect [13]. Inhibition or knocking down of
PDE3B has been shown to be beneficial at the level of the b-cells,
leading to improved insulin secretion [6,48]. However, other
metabolic effects of PDE3 inhibition have been associated with
overall non-beneficial metabolic phenotypes in mice and rats
[49,50]. It thus seems promising that inhibition of PDEs other
than PDE3 potentiates an effect of insulin secretion and can
therefore be more advantageous for the treatment of diabetes.
In summary, we conclude that PDE3B, a PDE isoform with
important functions in b-cells [7,8,11,15], is activated in response
to stimuli relevant for pancreatic b-cell function in rat islet and
INS-1 (832/13) cells and that activation is important in feedback
modulation/fine tuning of cAMP levels. In addition, increased
PDE3B activity is associated with increased as well as decreased
phosphorylation of the enzyme. We also conclude that PDE1,
PDE3, PDE4C, PDE7A, PDE8A and PDE10A are present in
human pancreatic islets.
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